SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors are associated with a reduction in body mass and pressure [28], improving cardiorenal outcomes [29]; GLP1-RA nowadays represents a second-line treatment in T2DM [30], and, as described for SGLT2 inhibitors, are associated with a reduction of cardiovascular risk, probably also thanks to crucial effects on renin-angiotensin system [31].